SJAR Bio-Tech

SJAR Bio-Tech is a clinical-stage biotechnology company headquartered in Shanghai, specializing in the discovery and development of innovative biologics with a primary focus on oncology. The company leverages its proprietary platform to design next-generation antibody-drug conjugates (ADCs) and multi-specific antibodies that offer improved safety and efficacy profiles compared to existing treatments. Its lead candidate, ESG-401, is a TROP2-directed ADC utilizing a stable linker and a topoisomerase I inhibitor payload, currently being evaluated in clinical trials for various solid tumors. SJAR Bio-Tech is supported by prominent venture capital firms and maintains a strategic focus on the global oncology market.